APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Antisense Oligonucleotide Therapies

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Antisense Oligonucleotide Therapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173966590331 December 2025170 pages

Choose your research edition.

Industry ResearchAntisense Oligonucleotide Therapies Industry Research Report 2026103 pages · $2,950 USDIndustry Growth & TrendsGlobal Antisense Oligonucleotide Therapies Industry Growth and Trends Forecast to 203261 pages · $3,450 USDMarket StructureGlobal Antisense Oligonucleotide Therapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antisense Oligonucleotide Therapies Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Antisense Oligonucleotide Therapies Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Antisense Oligonucleotide Therapies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Antisense Oligonucleotide Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antisense Oligonucleotide Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antisense Oligonucleotide Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Antisense Oligonucleotide Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antisense Oligonucleotide Therapies include Sarepta Therapeutics, Nippon Shinyaku and Ionis Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Antisense Oligonucleotide Therapies market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antisense Oligonucleotide Therapies and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antisense Oligonucleotide Therapies revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Antisense Oligonucleotide Therapies market size, projected growth trends, production technologies, key applications, and end-use industries.

Antisense Oligonucleotide Therapies Segment by Company

Sarepta Therapeutics

Nippon Shinyaku

Ionis Pharmaceuticals

Antisense Oligonucleotide Therapies Segment by Type

Without GalNAc-conjugated

With GalNAc-conjugated

Antisense Oligonucleotide Therapies Segment by Application

Cancer

Cardiovascular Diseases

Genetic Disease

Other

Antisense Oligonucleotide Therapies Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antisense Oligonucleotide Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antisense Oligonucleotide Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antisense Oligonucleotide Therapies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Antisense Oligonucleotide Therapies in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antisense Oligonucleotide Therapies industry.

Chapter 3: Detailed analysis of Antisense Oligonucleotide Therapies companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antisense Oligonucleotide Therapiesrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Without GalNAc-conjugated Table 3. Key Players of With GalNAc-conjugated Table 4. Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Cancer Table 6. Key Players of Cardiovascular Diseases Table 7. Key Players of Genetic Disease Table 8. Key Players of Other Table 9. Global Antisense Oligonucleotide Therapies Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Antisense Oligonucleotide Therapies Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Antisense Oligonucleotide Therapies Market Share by Region (2021-2026) Table 12. Global Antisense Oligonucleotide Therapies Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Antisense Oligonucleotide Therapies Market Share by Region (2027-2032) Table 14. Antisense Oligonucleotide Therapies Industry Trends Table 15. Antisense Oligonucleotide Therapies Industry Drivers Table 16. Antisense Oligonucleotide Therapies Industry Opportunities and Challenges Table 17. Antisense Oligonucleotide Therapies Industry Restraints Table 18. Global Antisense Oligonucleotide Therapies Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Antisense Oligonucleotide Therapies Revenue Market Share by Company (2021-2026) Table 20. Global Antisense Oligonucleotide Therapies Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Antisense Oligonucleotide Therapies Key Company Head Office and Area Served Table 22. Global Antisense Oligonucleotide Therapies Company, Product Type & Application Table 23. Global Antisense Oligonucleotide Therapies Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Antisense Oligonucleotide Therapies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Antisense Oligonucleotide Therapies Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Antisense Oligonucleotide Therapies Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Antisense Oligonucleotide Therapies Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Antisense Oligonucleotide Therapies Revenue Market Share by Type (2021-2026) Table 30. Global Antisense Oligonucleotide Therapies Revenue Market Share by Type (2027-2032) Table 31. Global Antisense Oligonucleotide Therapies Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Antisense Oligonucleotide Therapies Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Antisense Oligonucleotide Therapies Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Antisense Oligonucleotide Therapies Revenue Market Share by Application (2021-2026) Table 35. Global Antisense Oligonucleotide Therapies Revenue Market Share by Application (2027-2032) Table 36. Sarepta Therapeutics Company Information Table 37. Sarepta Therapeutics Business Overview Table 38. Sarepta Therapeutics Antisense Oligonucleotide Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Sarepta Therapeutics Antisense Oligonucleotide Therapies Product Portfolio Table 40. Sarepta Therapeutics Recent Development Table 41. Nippon Shinyaku Company Information Table 42. Nippon Shinyaku Business Overview Table 43. Nippon Shinyaku Antisense Oligonucleotide Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Nippon Shinyaku Antisense Oligonucleotide Therapies Product Portfolio Table 45. Nippon Shinyaku Recent Development Table 46. Ionis Pharmaceuticals Company Information Table 47. Ionis Pharmaceuticals Business Overview Table 48. Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Product Portfolio Table 50. Ionis Pharmaceuticals Recent Development Table 51. North America Antisense Oligonucleotide Therapies Market Size by Type (2021-2026) & (US$ Million) Table 52. North America Antisense Oligonucleotide Therapies Market Size by Type (2027-2032) & (US$ Million) Table 53. North America Antisense Oligonucleotide Therapies Market Size by Application (2021-2026) & (US$ Million) Table 54. North America Antisense Oligonucleotide Therapies Market Size by Application (2027-2032) & (US$ Million) Table 55. North America Antisense Oligonucleotide Therapies Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 56. North America Antisense Oligonucleotide Therapies Market Size by Country (2021-2026) Table 57. North America Antisense Oligonucleotide Therapies Market Size by Country (2027-2032) Table 58. Europe Antisense Oligonucleotide Therapies Market Size by Type (2021-2026) & (US$ Million) Table 59. Europe Antisense Oligonucleotide Therapies Market Size by Type (2027-2032) & (US$ Million) Table 60. Europe Antisense Oligonucleotide Therapies Market Size by Application (2021-2026) & (US$ Million) Table 61. Europe Antisense Oligonucleotide Therapies Market Size by Application (2027-2032) & (US$ Million) Table 62. Europe Antisense Oligonucleotide Therapies Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 63. Europe Antisense Oligonucleotide Therapies Market Size by Country (2021-2026) Table 64. Europe Antisense Oligonucleotide Therapies Market Size by Country (2027-2032) Table 65. China Antisense Oligonucleotide Therapies Market Size by Type (2021-2026) & (US$ Million) Table 66. China Antisense Oligonucleotide Therapies Market Size by Type (2027-2032) & (US$ Million) Table 67. China Antisense Oligonucleotide Therapies Market Size by Application (2021-2026) & (US$ Million) Table 68. China Antisense Oligonucleotide Therapies Market Size by Application (2027-2032) & (US$ Million) Table 69. Asia Antisense Oligonucleotide Therapies Market Size by Type (2021-2026) & (US$ Million) Table 70. Asia Antisense Oligonucleotide Therapies Market Size by Type (2027-2032) & (US$ Million) Table 71. Asia Antisense Oligonucleotide Therapies Market Size by Application (2021-2026) & (US$ Million) Table 72. Asia Antisense Oligonucleotide Therapies Market Size by Application (2027-2032) & (US$ Million) Table 73. Asia Antisense Oligonucleotide Therapies Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 74. Asia Antisense Oligonucleotide Therapies Market Size by Country (2021-2026) Table 75. Asia Antisense Oligonucleotide Therapies Market Size by Country (2027-2032) Table 76. South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Type (2021-2026) & (US$ Million) Table 77. South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Type (2027-2032) & (US$ Million) Table 78. South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Application (2021-2026) & (US$ Million) Table 79. South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Application (2027-2032) & (US$ Million) Table 80. South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 81. South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Country (2021-2026) Table 82. South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Country (2027-2032) Table 83. Research Programs/Design for This Report Table 84. Authors List of This Report Table 85. Secondary Sources Table 86. Primary Sources List of Figures Figure 1. Antisense Oligonucleotide Therapies Product Image Figure 2. Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Antisense Oligonucleotide Therapies Market Share by Type: 2025 VS 2032 Figure 4. Without GalNAc-conjugated Image Figure 5. With GalNAc-conjugated Image Figure 6. Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Antisense Oligonucleotide Therapies Market Share by Application: 2025 VS 2032 Figure 8. Cancer Image Figure 9. Cardiovascular Diseases Image Figure 10. Genetic Disease Image Figure 11. Other Image Figure 12. Global Antisense Oligonucleotide Therapies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 14. Global Antisense Oligonucleotide Therapies Market Share by Region: 2025 VS 2032 Figure 15. Years Considered Figure 16. Global Antisense Oligonucleotide Therapies Market Share by Players in 2025 Figure 17. Global Top 5 and 10 Antisense Oligonucleotide Therapies Players Market Share by Revenue in 2025 Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Antisense Oligonucleotide Therapies Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Antisense Oligonucleotide Therapies Revenue Market Share by Type (2021-2032) Figure 21. Global Antisense Oligonucleotide Therapies Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Antisense Oligonucleotide Therapies Revenue Market Share by Application (2021-2032) Figure 23. North America Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 24. North America Antisense Oligonucleotide Therapies Market Share by Type (2021-2032) Figure 25. North America Antisense Oligonucleotide Therapies Market Share by Application (2021-2032) Figure 26. North America Antisense Oligonucleotide Therapies Market Share by Country (2021-2032) Figure 27. United States Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 28. Canada Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 29. Mexico Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 30. Europe Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 31. Europe Antisense Oligonucleotide Therapies Market Share by Type (2021-2032) Figure 32. Europe Antisense Oligonucleotide Therapies Market Share by Application (2021-2032) Figure 33. Europe Antisense Oligonucleotide Therapies Market Share by Country (2021-2032) Figure 34. Germany Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 35. France Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 36. U.K. Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 37. Italy Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 38. Russia Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 39. Nordic Countries Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 40. China Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 41. China Antisense Oligonucleotide Therapies Market Share by Type (2021-2032) Figure 42. China Antisense Oligonucleotide Therapies Market Share by Application (2021-2032) Figure 43. Asia Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 44. Asia Antisense Oligonucleotide Therapies Market Share by Type (2021-2032) Figure 45. Asia Antisense Oligonucleotide Therapies Market Share by Application (2021-2032) Figure 46. Asia Antisense Oligonucleotide Therapies Market Share by Country (2021-2032) Figure 47. Japan Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 48. South Korea Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 49. Taiwan Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 50. Southeast Asia Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 51. India Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 52. Australia Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Share by Type (2021-2032) Figure 55. South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Share by Application (2021-2032) Figure 56. South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Share by Country (2021-2032) Figure 57. Brazil Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 58. South Africa Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 60. Turkey Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 61. Argentina Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 62. UAE Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 63. Egypt Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 64. Chile Antisense Oligonucleotide Therapies Market Size (2021-2032) & (US$ Million) Figure 65. Research Process Figure 66. Key Executives Interviewed

Scope & coverage.

Types
  • Without GalNAc-conjugated
  • With GalNAc-conjugated
Applications
  • Cancer
  • Cardiovascular Diseases
  • Genetic Disease
  • Other
Companies covered
  • Sarepta Therapeutics
  • Nippon Shinyaku
  • Ionis Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Without GalNAc-conjugated
  5. 1.2.3 With GalNAc-conjugated
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Cancer
  9. 1.3.3 Cardiovascular Diseases
  10. 1.3.4 Genetic Disease
  11. 1.3.5 Other
  12. 1.4 Global Market Growth Prospects
  13. 1.5 Global Antisense Oligonucleotide Therapies Growth Trends by Region
  14. 1.5.1 Global Antisense Oligonucleotide Therapies Market Size by Region: 2021 VS 2025 VS 2032
  15. 1.5.2 Antisense Oligonucleotide Therapies Market Size by Region (2021-2026)
  16. 1.5.3 Antisense Oligonucleotide Therapies Market Size by Region (2027-2032)
  17. 1.6 Assumptions and Limitations
  18. 1.7 Study Goals and Objectives
  19. 1.8 Years Considered
2 Global Antisense Oligonucleotide Therapies Market Dynamics
  1. 2.1 Antisense Oligonucleotide Therapies Industry Trends
  2. 2.2 Antisense Oligonucleotide Therapies Industry Drivers
  3. 2.3 Antisense Oligonucleotide Therapies Industry Opportunities and Challenges
  4. 2.4 Antisense Oligonucleotide Therapies Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Antisense Oligonucleotide Therapies Revenue by Company (2021-2026)
  2. 3.2 Global Antisense Oligonucleotide Therapies Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Antisense Oligonucleotide Therapies Key Company Head office and Area Served
  4. 3.4 Global Antisense Oligonucleotide Therapies Company, Product Type & Application
  5. 3.5 Global Antisense Oligonucleotide Therapies Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Antisense Oligonucleotide Therapies Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Antisense Oligonucleotide Therapies Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Antisense Oligonucleotide Therapies Tier 1, Tier 2, and Tier 3
4 Antisense Oligonucleotide Therapies Market by Type
  1. 4.1 Global Antisense Oligonucleotide Therapies Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Antisense Oligonucleotide Therapies Market Size by Type (2021-2032)
  3. 4.3 Global Antisense Oligonucleotide Therapies Market Size Share by Type (2021-2032)
5 Antisense Oligonucleotide Therapies Market by Application
  1. 5.1 Global Antisense Oligonucleotide Therapies Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Antisense Oligonucleotide Therapies Market Size by Application (2021-2032)
  3. 5.3 Global Antisense Oligonucleotide Therapies Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Sarepta Therapeutics
  2. 6.1.1 Sarepta Therapeutics Company Information
  3. 6.1.2 Sarepta Therapeutics Business Overview
  4. 6.1.3 Sarepta Therapeutics Antisense Oligonucleotide Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Sarepta Therapeutics Antisense Oligonucleotide Therapies Product Portfolio
  6. 6.1.5 Sarepta Therapeutics Recent Developments
  7. 6.2 Nippon Shinyaku
  8. 6.2.1 Nippon Shinyaku Company Information
  9. 6.2.2 Nippon Shinyaku Business Overview
  10. 6.2.3 Nippon Shinyaku Antisense Oligonucleotide Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Nippon Shinyaku Antisense Oligonucleotide Therapies Product Portfolio
  12. 6.2.5 Nippon Shinyaku Recent Developments
  13. 6.3 Ionis Pharmaceuticals
  14. 6.3.1 Ionis Pharmaceuticals Company Information
  15. 6.3.2 Ionis Pharmaceuticals Business Overview
  16. 6.3.3 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Product Portfolio
  18. 6.3.5 Ionis Pharmaceuticals Recent Developments
7 North America
  1. 7.1 North America Antisense Oligonucleotide Therapies Market Size (2021-2032)
  2. 7.2 North America Antisense Oligonucleotide Therapies Market Size by Type
  3. 7.2.1 North America Antisense Oligonucleotide Therapies Market Size by Type (2021-2026)
  4. 7.2.2 North America Antisense Oligonucleotide Therapies Market Size by Type (2027-2032)
  5. 7.2.3 North America Antisense Oligonucleotide Therapies Market Share by Type (2021-2032)
  6. 7.3 North America Antisense Oligonucleotide Therapies Market Size by Application
  7. 7.3.1 North America Antisense Oligonucleotide Therapies Market Size by Application (2021-2026)
  8. 7.3.2 North America Antisense Oligonucleotide Therapies Market Size by Application (2027-2032)
  9. 7.3.3 North America Antisense Oligonucleotide Therapies Market Share by Application (2021-2032)
  10. 7.4 North America Antisense Oligonucleotide Therapies Market Size by Country
  11. 7.4.1 North America Antisense Oligonucleotide Therapies Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Antisense Oligonucleotide Therapies Market Size by Country (2021-2026)
  13. 7.4.3 North America Antisense Oligonucleotide Therapies Market Size by Country (2027-2032)
  14. 7.4.4 North America Antisense Oligonucleotide Therapies Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Antisense Oligonucleotide Therapies Market Size (2021-2032)
  2. 8.2 Europe Antisense Oligonucleotide Therapies Market Size by Type
  3. 8.2.1 Europe Antisense Oligonucleotide Therapies Market Size by Type (2021-2026)
  4. 8.2.2 Europe Antisense Oligonucleotide Therapies Market Size by Type (2027-2032)
  5. 8.2.3 Europe Antisense Oligonucleotide Therapies Market Share by Type (2021-2032)
  6. 8.3 Europe Antisense Oligonucleotide Therapies Market Size by Application
  7. 8.3.1 Europe Antisense Oligonucleotide Therapies Market Size by Application (2021-2026)
  8. 8.3.2 Europe Antisense Oligonucleotide Therapies Market Size by Application (2027-2032)
  9. 8.3.3 Europe Antisense Oligonucleotide Therapies Market Share by Application (2021-2032)
  10. 8.4 Europe Antisense Oligonucleotide Therapies Market Size by Country
  11. 8.4.1 Europe Antisense Oligonucleotide Therapies Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Antisense Oligonucleotide Therapies Market Size by Country (2021-2026)
  13. 8.4.3 Europe Antisense Oligonucleotide Therapies Market Size by Country (2027-2032)
  14. 8.4.4 Europe Antisense Oligonucleotide Therapies Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Antisense Oligonucleotide Therapies Market Size (2021-2032)
  2. 9.2 China Antisense Oligonucleotide Therapies Market Size by Type
  3. 9.2.1 China Antisense Oligonucleotide Therapies Market Size by Type (2021-2026)
  4. 9.2.2 China Antisense Oligonucleotide Therapies Market Size by Type (2027-2032)
  5. 9.2.3 China Antisense Oligonucleotide Therapies Market Share by Type (2021-2032)
  6. 9.3 China Antisense Oligonucleotide Therapies Market Size by Application
  7. 9.3.1 China Antisense Oligonucleotide Therapies Market Size by Application (2021-2026)
  8. 9.3.2 China Antisense Oligonucleotide Therapies Market Size by Application (2027-2032)
  9. 9.3.3 China Antisense Oligonucleotide Therapies Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Antisense Oligonucleotide Therapies Market Size (2021-2032)
  2. 10.2 Asia Antisense Oligonucleotide Therapies Market Size by Type
  3. 10.2.1 Asia Antisense Oligonucleotide Therapies Market Size by Type (2021-2026)
  4. 10.2.2 Asia Antisense Oligonucleotide Therapies Market Size by Type (2027-2032)
  5. 10.2.3 Asia Antisense Oligonucleotide Therapies Market Share by Type (2021-2032)
  6. 10.3 Asia Antisense Oligonucleotide Therapies Market Size by Application
  7. 10.3.1 Asia Antisense Oligonucleotide Therapies Market Size by Application (2021-2026)
  8. 10.3.2 Asia Antisense Oligonucleotide Therapies Market Size by Application (2027-2032)
  9. 10.3.3 Asia Antisense Oligonucleotide Therapies Market Share by Application (2021-2032)
  10. 10.4 Asia Antisense Oligonucleotide Therapies Market Size by Country
  11. 10.4.1 Asia Antisense Oligonucleotide Therapies Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Antisense Oligonucleotide Therapies Market Size by Country (2021-2026)
  13. 10.4.3 Asia Antisense Oligonucleotide Therapies Market Size by Country (2027-2032)
  14. 10.4.4 Asia Antisense Oligonucleotide Therapies Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Antisense Oligonucleotide Therapies Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst